Literature DB >> 34860745

Development of a Prognostic Model for Predicting Multiple Sclerosis After Optic Neuritis: A Secondary Analysis of Data From the Optic Neuritis Treatment Trial.

Wenjing Luo1, Xinlei Deng, Xiaoyu Xu, Ruitong Song, Meifeng Luo, Heather E Moss, Yi Du.   

Abstract

BACKGROUND: Optic neuritis can be the initial manifestation of multiple sclerosis (MS). The purpose of this study was to develop a prognostic model for predicting the risk of MS development among patients with optic neuritis.
METHODS: The data from 388 patients with optic neuritis were retrieved from the Optic Neuritis Treatment Trial (ONTT). Cox proportional hazards regression analysis was used to develop a prognostic model. The performance of the model was assessed by using Harrell's C-index and calibration curves. The rates of MS development were estimated using the Kaplan-Meier method.
RESULTS: Among the enrolled subjects, a total of 154 (39.7%) patients developed clinically definite MS during a median follow-up period of 15.8 years (interquartile range, 7.2-16.9 years). The factors associated with the development of MS were the presence of brain lesions as on baseline MRI, previous nonspecific neurologic symptoms, commencing low-dose corticosteroids treatment, ocular pain, and absence of optic disc/peripapillary hemorrhage. After incorporating these 5 factors into the prognostic model, a C-index of 0.72 (95% confidence interval [CI], 0.69-0.76) and good calibration curves were obtained. The C-index of the model was significantly higher than the C-indexes of any single factor (P < 0.001 in all cases). The model was able to stratify the ONTT patient cohort into 3 risk groups with significantly different intergroup rates of developing MS (rates for developing MS within a 15-year period: high-risk group, 75.7% [95% CI, 65.6%-82.9%], intermediate-risk group, 44.7% [95% CI, 31.4%-55.4%]; and low-risk group, 20.8% [95% CI, 14.2%-26.8%]; log-rank P < 0.001).
CONCLUSIONS: This prognostic model had a better prediction ability when compared with the standard practice that relies solely on using brain lesions on MRI. It can, therefore, help guide decision-making to initiate earlier disease-modifying therapy for patients with optic neuritis at risk of developing MS.
Copyright © 2021 by North American Neuro-Ophthalmology Society.

Entities:  

Mesh:

Year:  2021        PMID: 34860745      PMCID: PMC9159903          DOI: 10.1097/WNO.0000000000001424

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   4.415


  35 in total

Review 1.  Optic neuritis in the era of biomarkers.

Authors:  John J Chen; Sean J Pittock; Eoin P Flanagan; Vanda A Lennon; M Tariq Bhatti
Journal:  Surv Ophthalmol       Date:  2019-08-16       Impact factor: 6.048

Review 2.  Multiple Sclerosis.

Authors:  Bassem I Yamout; Raed Alroughani
Journal:  Semin Neurol       Date:  2018-05-23       Impact factor: 3.420

3.  Disease-modifying therapies for multiple sclerosis.

Authors:  Floriana De Angelis; Nevin A John; Wallace J Brownlee
Journal:  BMJ       Date:  2018-11-27

4.  The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

Authors: 
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Neurological outcome and predictive factors of idiopathic optic neuritis in China.

Authors:  Jing-ting Peng; Heng-ri Cong; Rong Yan; Xiu-yun Kong; Han-qiu Jiang; Wen-bin Wei; Xiao-jun Zhang
Journal:  J Neurol Sci       Date:  2014-12-27       Impact factor: 3.181

7.  Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI.

Authors:  Inês Brás Marques; Fernando Matias; Eduardo Duarte Silva; Luis Cunha; Lívia Sousa
Journal:  J Clin Neurosci       Date:  2013-08-23       Impact factor: 1.961

8.  Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study.

Authors:  Arash Kheradvar; Abdol Reza Tabassi; Behrouz Nikbin; Farideh Khosravi; Mehrnaz Naroueynejad; Batool Moradi; Ali Akbar Amirzargar
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

9.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Authors: 
Journal:  Arch Neurol       Date:  2008-06

Review 10.  Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-06       Impact factor: 44.182

View more
  1 in total

1.  Anti-inflammatory effect of miR-125a-5p on experimental optic neuritis by promoting the differentiation of Treg cells.

Authors:  Jia-Lin Zhan; Yan-Ling Huang; Qiao-Wen Liang; Xiao-Sheng Qu; Zi-Mei Dong; Yi Du; Wen-Jing Luo
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.